These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33710795)

  • 1. Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance.
    Nishino M; Suda K; Koga T; Ohara S; Fujino T; Soh J; Tirunagaru V; Vellanki A; Doebele RC; Mitsudomi T
    Thorac Cancer; 2021 May; 12(10):1511-1516. PubMed ID: 33710795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
    Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS
    J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and mechanism of acquired resistance to tarloxotinib in
    Koga T; Suda K; Nishino M; Fujino T; Ohara S; Hamada A; Soh J; Tirunagaru V; Vellanki A; Doebele RC; Mitsudomi T
    Transl Lung Cancer Res; 2021 Aug; 10(8):3659-3670. PubMed ID: 34584864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
    Hamada A; Suda K; Nishino M; Obata K; Oiki H; Fukami T; Fukuda S; Fujino T; Ohara S; Koga T; Chiba M; Shimoji M; Ito M; Takemoto T; Soh J; Tsutani Y; Mitsudomi T
    J Thorac Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 37666482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
    Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
    Estrada-Bernal A; Le AT; Doak AE; Tirunagaru VG; Silva S; Bull MR; Smaill JB; Patterson AV; Kim C; Liu SV; Doebele RC
    Clin Cancer Res; 2021 Mar; 27(5):1463-1475. PubMed ID: 33355298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
    Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
    Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
    Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
    Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations.
    Kagawa Y; Hayashida T; Liu J; Mori S; Izumi H; Kumagai S; Udagawa H; Hattori N; Goto K; Kobayashi SS
    JTO Clin Res Rep; 2023 Mar; 4(3):100462. PubMed ID: 36915628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
    Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
    He M; Capelletti M; Nafa K; Yun CH; Arcila ME; Miller VA; Ginsberg MS; Zhao B; Kris MG; Eck MJ; Jänne PA; Ladanyi M; Oxnard GR
    Clin Cancer Res; 2012 Mar; 18(6):1790-7. PubMed ID: 22190593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Hirose T; Ikegami M; Endo M; Matsumoto Y; Nakashima Y; Mano H; Kohsaka S
    Lung Cancer; 2021 Feb; 152():135-142. PubMed ID: 33395611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study.
    Fukuda S; Suda K; Hamada A; Oiki H; Ohara S; Ito M; Soh J; Mitsudomi T; Tsutani Y
    Biomedicines; 2024 Jun; 12(7):. PubMed ID: 39061985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.